Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease-Reference-Cited by-同舟云学术

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease

Published:2013-08-30 Issue:3 Volume:28 Page:658-665
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Bachanova V^ORCID,Marks D I,Zhang M-J,Wang H,de Lima M,Aljurf M D,Arellano M,Artz A S,Bacher U,Cahn J-Y,Chen Y-B,Copelan E A,Drobyski W R,Gale R P,Greer J P,Gupta V,Hale G A,Kebriaei P,Lazarus H M,Lewis I D,Lewis V A,Liesveld J L,Litzow M R,Loren A W,Miller A M,Norkin M,Oran B,Pidala J,Rowe J M,Savani B N,Saber W,Vij R,Waller E K,Wiernik P H,Weisdorf D J

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2013253.pdf

Reference42 articles.

1. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109: 3189–3197.

2. Mizuta S, Matsuo K, Yagasaki F, Yujiri T, Hatta Y, Kimura Y et al. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia 2011; 25: 41–47.

3. Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Duhrsen U et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007; 109: 2068–2076.

4. Tanguy-Schmidt A, Rousselot P, Chalandon Y, Cayuela JM, Hayette S, Vekemans MC et al. Long-term follow-up of the imatinib GRAAPH-2003 Study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL Study. Biol Blood Marrow Transplant 2013; 19: 150–155.

5. Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 2009; 113: 4489–4496.

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

2. Reduced‐intensity therapy for relapsed Philadelphia chromosome‐positive leukemia;Pediatric Blood & Cancer;2023-12-05

3. Effect of Conditioning Regimens and Graft-versus-Host Disease Prophylaxis on the Outcomes of Umbilical Cord Blood Transplantation Performed with Cyclophosphamide/Total Body Irradiation-Based Regimens;Transplantation and Cellular Therapy;2023-12

4. Reduced-intensity allogenic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia;Annals of Hematology;2023-11-25

5. Myeloablative or reduced-intensity/non-myeloablative hematopoietic cell transplantation for Philadelphia-positive acute lymphoblastic leukemia in adults older than 40 years old — a secondary analysis of a CIBMTR database;Annals of Hematology;2023-11-09